These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 8552653)
1. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Gozes I; Bardea A; Reshef A; Zamostiano R; Zhukovsky S; Rubinraut S; Fridkin M; Brenneman DE Proc Natl Acad Sci U S A; 1996 Jan; 93(1):427-32. PubMed ID: 8552653 [TBL] [Abstract][Full Text] [Related]
2. Protection against developmental deficiencies by a lipophilic VIP analogue. Gozes I; Bachar M; Bardea A; Davidson A; Rubinraut S; Fridkin M Neurochem Res; 1998 May; 23(5):689-93. PubMed ID: 9566607 [TBL] [Abstract][Full Text] [Related]
3. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Gozes I; Perl O; Giladi E; Davidson A; Ashur-Fabian O; Rubinraut S; Fridkin M Proc Natl Acad Sci U S A; 1999 Mar; 96(7):4143-8. PubMed ID: 10097177 [TBL] [Abstract][Full Text] [Related]
4. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Gozes I; Bardea A; Bechar M; Pearl O; Reshef A; Zamostiano R; Davidson A; Rubinraut S; Giladi E; Fridkin M; Brenneman DE Ann N Y Acad Sci; 1997 Apr; 814():161-6. PubMed ID: 9160968 [No Abstract] [Full Text] [Related]
5. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration. Cui X; Cao DY; Wang ZM; Zheng AP Pharmazie; 2013 Jan; 68(1):69-74. PubMed ID: 23444784 [TBL] [Abstract][Full Text] [Related]
6. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. Gozes I; Giladi E; Pinhasov A; Bardea A; Brenneman DE J Pharmacol Exp Ther; 2000 Jun; 293(3):1091-8. PubMed ID: 10869414 [TBL] [Abstract][Full Text] [Related]
7. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. Gozes I; Bachar M; Bardea A; Davidson A; Rubinraut S; Fridkin M; Giladi E J Neurobiol; 1997 Sep; 33(3):329-42. PubMed ID: 9298769 [TBL] [Abstract][Full Text] [Related]
8. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884 [TBL] [Abstract][Full Text] [Related]
9. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Ashur-Fabian O; Perl O; Lilling G; Fridkin M; Gozes I Peptides; 1999; 20(5):629-33. PubMed ID: 10465516 [TBL] [Abstract][Full Text] [Related]
10. Effects of repeated administration of (-)-nicotine on AF64A-induced learning and memory impairment in rats. Hiramatsu M; Yamatsu T; Kameyama T; Nabeshima T J Neural Transm (Vienna); 2002 Mar; 109(3):361-75. PubMed ID: 11956957 [TBL] [Abstract][Full Text] [Related]
11. Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression. Ivanova M; Belcheva S; Belcheva I; Negrev N; Tashev R Psychopharmacology (Berl); 2012 Jun; 221(4):561-74. PubMed ID: 22160165 [TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Ashur-Fabian O; Giladi E; Furman S; Steingart RA; Wollman Y; Fridkin M; Brenneman DE; Gozes I Neurosci Lett; 2001 Jul; 307(3):167-70. PubMed ID: 11438390 [TBL] [Abstract][Full Text] [Related]
14. Harpagoside ameliorates the amyloid-β-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. Li J; Ding X; Zhang R; Jiang W; Sun X; Xia Z; Wang X; Wu E; Zhang Y; Hu Y Neuroscience; 2015 Sep; 303():103-14. PubMed ID: 26135675 [TBL] [Abstract][Full Text] [Related]
15. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014 [TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. Gressens P; Marret S; Hill JM; Brenneman DE; Gozes I; Fridkin M; Evrard P J Clin Invest; 1997 Jul; 100(2):390-7. PubMed ID: 9218516 [TBL] [Abstract][Full Text] [Related]
17. Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid. Dudas B; Hanin I; Rose M; Wülfert E Neurobiol Dis; 2004 Mar; 15(2):262-8. PubMed ID: 15006696 [TBL] [Abstract][Full Text] [Related]
18. Lateralized learning and memory effects of vasoactive intestinal peptide infused into the rat hippocampal CA1 area. Ivanova M; Ternianov A; Tashev R; Belcheva S; Belcheva I Regul Pept; 2009 Aug; 156(1-3):42-6. PubMed ID: 19465061 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. Delgado M; Ganea D FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429 [TBL] [Abstract][Full Text] [Related]
20. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. Steingart RA; Solomon B; Brenneman DE; Fridkin M; Gozes I J Mol Neurosci; 2000 Dec; 15(3):137-45. PubMed ID: 11303778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]